Member Info for Steadydanny

In fairness if there were any shenanigans ahead
then I suspect they have/are already happening given the wombles bashing here. Pound to a penny Jacob Rees Moggs Somerset Capital Investment would be privy to The Edison reports and he was actually my guess re 'honoured'.
The second and third HNWI were happy to pay £1m @7p and £1m @ 8.25p respectively.
If they were happy to pay that the shorters derampers would have seen this like a flare going off for a company not on their radar previously.
I'm convinced that's why the sp given our ipr and news and patents and oversea updates etc etc is definitely being 'manipulated' or played and they have been trying to get hold of stop losses or weakened holders.
Trouble for them is I think a great majority of shares are being held by those who did their research and they are sat on their hands.
Really looking forward to the QandA.
All best Steady.

Morning again SOG. The patent that was posted re the crystalline compound had a tab on it which showed areas of protection. I mentioned that it had two sections, firstly global in which it listed I believe most of the world including China and then regards the US it had I believe all the states in alphabetical order.
So I believe we have everywhere between the North and south Pole covered. Atleast that's what I took from it.
Anyways off out now. All best steady.

Morning SOG.
All sounding positive. Have a great day.

That's the bonus. Or do they license the algorithm and take a percentage from those where energy usage is top news and trillions set aside for governments to embrace lower energy usage?

Cheers Mafuta. I did drop a hint re qbt as I like the majority of posters here and saw the Novacyt shenanigans before take off. It's about finding a company that is focused and has future scope. Which imo have a similar platform to the progress in mc increase here.

When the market wakes up..this from our board...note the 1802 x2 grant response but the additional relatively sublime comment which has yet to be RNSd!!

Additionally, a patent application describing a number of crystalline forms of a TYK2 inhibitor for medicinal applications, filed by Sareum in April 2020, was published on 14 October 2021. This type of patent is standard pharmaceutical industry practice and an important step to fully protect the intellectual property surrounding the Company's research programmes and to extend the life span of its patent portfolio.
I'm going to bed. Early coastal walk. Sincerely can't believe this is not a major discussion here.

Mafuta this
Intellectual Property

The Company had two new US patents granted during 2021 (in January and September) that reinforce the patent protection for SDC-1802 and its use in treating certain cancers (including pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma) by inhibiting TYK2 kinase.

Additionally, a patent application describing a number of crystalline forms of a TYK2 inhibitor for medicinal applications, filed by Sareum in April 2020, was published on 14 October 2021. This type of patent is standard pharmaceutical industry practice and an important step to fully protect the intellectual property surrounding the Company's research programmes and to extend the life span of its patent portfolio.

17 years? Submarine? Why have we had trolls?
Best wishes to sareum holders.

Hi Mafuta
This
• Two new US patents granted (January and September 2021) strengthening patent protection, which is now in place across all major territories
Sounds like the submarine patent
And then
The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development.
And a post of mine earlier
Therefore, when the patent examiner “allows” your patent application, you do not let it “grant.” That would start your 17-year term. Rather, you file a “continuation” to keep it “underwater” or “pending.” During this time, competitors develop and adopt the technology. Once the industry embraces the technology, you finally allow your submarine patent to “surface.” This starts your 17-year patent term. However, now the technology is ubiquitous and you have greater leverage to force a settlement or payout.
So it's not necessarily about it being granted! It's a submarine patent!! So a continuation or pending can be reported in a RNS.
I doubt an epistolary RNS will be as per usual between the board and investors. I expect more than that.
I don't think we have officially accepted the grant, hence no RNS yesterday.

Evening SOG. Re 1802
My thoughts on the Q and A is that they will only respond to official responses via RNSs reported. So the submarine patent is able to be ignored if a question arises.
That's why as I mentioned 2 days ago is that the updated 1802 patent would officially 'grant' yesterday. But our TU seemed to skip it on the 25th and just state it was granted as per September RNS. Which technically is not correct.it was purely set for approval which would be granted yesterday. Of which we have had no official update. That's where I scratch my head.
It's as if official reporting on 1802 is being stalled for some purpose.
Am I overthinking?
Just seems the recent negative/disruptive posts with no tangible substance to substantiate their posts are as apparent as around the Edison report and a month later the first HNWI Subscription. We all remember senator and sly...have we seen those names since....or are they incognito with similar negative posting techniques?

I would like the boards response to this extract (particularly lupus part) from the Edison report which a month later saw our first HNWI Subscription
'The autoimmune space is highly competitive (dominated by big pharma) and while PS will be the likely focus for SDC-1801's Phase Ia clinical study (easiest to recruit; potential c $40bn market, albeit a very crowded one), we expect Sareum to get better mileage from prospecting other, less explored, autoimmune conditions such as lupus ($1.9bn market but less crowded) and inflammatory bowel disease (IBD - $16bn market) where its dual action may offer greater therapeutic gains.'

Hi SOG.
Thanks re the lupus details. Lots of interesting stuff. When you say skyryder is that a typo...

Given our drugs and the stages 1801 and 1802 are and our improved patent in US I just got to wondering on licensing.
GSK today have announced in January the appointment of NED Harry Dietz to their board to undertake research for new drugs and pipelines, (we all know about EW and Elliot issues and new pipelines required for split)..of which
his main research is fibrosis/fibrillins. Which from what I gather includes lupus from what I see our ipr would provide a suitable license for him to oversee at GSK given they have specifically hired this expert.
If that's right might that be why we have had you know who here?

Our new improved 1802 is being looked at with lupus in mind? Am I right/wrong on this

So do one now.

Ndr you are focusing on covid. We had a grant to look into covid. But 90 percent of our ipr is elsewhere. Why are you making covid sareums mainstay ipr reason of being?

Completed Covid-19 Research Project Delivers Encouraging Results

Cambridge, UK, 1 July 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce encouraging top-line results from its UKRI grant funded Covid-19 research project.

The aim of this research project was to investigate the effects of SDC-1801, the Company’s proprietary TYK2/JAK1 inhibitor, on cytokine signalling after SARS-CoV-2 infection. It was also designed to confirm whether an over-active inflammatory response (known as a ‘cytokine storm’) via the Interferon Type 1 pathway can be blocked in this disease by SDC-1801.

The project has completed on schedule, with the final results confirming the initial encouraging results as noted in the Company’s Interim Results, published on 23 April 2021. The results of the project found that SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to baricitinib, a JAK1/JAK2 inhibitor.

Subsequent completed in-vivo studies support the initial cellular results and indicate:

Strong evidence that expression of Type 1 interferons (IFNa and IFNb) is reduced by SDC-1801 treatment in a dose-responsive manner; and thatViral loads did not increase after SDC-1801 administration, a potential concern when anti-inflammatory agents are used to dampen down an over-active immune response

A secondary objective, the investigation into whether treatment with SDC-1801 in disease models could protect against bacterial pneumonia following SARS-CoV-2 infection was inconclusive, due to technical shortcomings in the disease model.

Subject to successful completion of the ongoing preclinical toxicology studies, requisite approvals and financing, the Company aims to commence Phase 1 clinical trials for SDC-1801 in early 2022. The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.

You are welcome.

Ndr give me 5 minutes to respond.

Gunner. As in the official update re 1802 would be 'granted' in the US today!? But our RNS posted yesterday said differently. They said granted before 26th October. It was only approved prior until today and I've not seen 'grant'' yet! Let's see what tomorrow brings. And the further tweak of 1802. Not too dissimilar from 1801.

Hi LeMajor.
I personally think we are being well and truly played. As WIP mentioned has ongoing experience in pharma and how they work It's business effectively. Greatly enjoy your posts WIP.
So here's a Steadydanny muse given the recent posts from 'some' posters re sp who are posting with nothing that backs up their tyre kicking. Really try and keep this brief. But factual points. The muse is your own approval or disproval.
I start 1st June.
HNWI #1 £900K @ 2.8P and a 1:5 Warrant option if +5p for 5 days.
15 June. HNWI #1 subscribes a further £1,47m @ 4.9p with a 1:3 Warrant if + 7p for 5 days.
14th July HNWI #1 exercises initial warrants to add £180k.
5 days later HNWI #2 Subscription of £1m @7p. With a 1:1 Warrant option if + 9p for 5 days.
Well # 1 if they want can add £490k as + 7p for 5 days.
Here is where it gets interesting imo. Third HNWI #3 Subscription of £1m at 8.25p with a 1:.25 option if above 10.25p for 5 days.
So given the 'posts' stipulating we are in a holding game and need to wait until next year. Well given Sareum's strategy and the fact HNWI #1 has put in £2.37m + £180k warrant it seems the price is being manipulated to prevent HNWI#2 +9p for +5 days as stepping in to assist if required which would give investor confidence! But the sp is being played for certain. Really think HNWI #3 would invest £1m @ 8.25p for a laugh?!
We are being well and truly played.
There is a reason we get wombles.
Regards Steadydanny

Great read. Also worth noting that Ask and Investor reports following the Update RNS are rather naughty. They say losses increase and dp drops 7.6% following release.
Could have said Sareum backed by recent significant HNWIs have secured ongoing funding for promising drug research further backed by a very experienced board who are drawing up best methodology for ongoing tests which could be taken on directly by sareum due to significant financial input. Also as per Sareums strategy they take their research to certain levels of pre clinical and are open to partnerships and licensing agreements for ongoing ipr continuation.
Bit naughty how if anyone wanted to look at Sareum as a portfolio addition they have the initial reports pop up.
Hopefully the diligent investors will see beyond the negative spin and read the excellent posts here....that is unless the cws baiting gets them removed as per their handlers orders.
Probably why they are struggling as those holding ain't phased.